Navigation Links
Celgosivir in Medical News

MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study

VANCOUVER, and SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, has received preliminary four-week interim results from a Phase II viral kinetics study in hepatitis C virus ("HCV") treatment-naive patie...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...erferon II-58 Nautilus Biotech Commences Phase I Study for Belerofon(R) II-58 Migenix Announces Phase II Proof-of-Concept Study Results of celgosivir II-59 Pharmasset Begins Multiple Dose-Escalating Study of R7128 II-59 Transgene Commences Phase I Trial of TG4040 II-59 Debiopharm Release...
Celgosivir in Medical Technology

New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders

Data to be Presented April 15th at EASL Conference in Barcelona, Spain VANCOUVER and SAN DIEGO, CA, April 11, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases, has received new top-line results confirming the previously announced clinical res...

Migenix to Present Celgosivir Phase II Hepatitis C Results at Digestive Disease Week 2007

VANCOUVER and SAN DIEGO, May 18, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases will make a presentation of results from a recent hepatitis C Phase II combination therapy study (see April 11, 2007 press release) in a non-responder patient p...

Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting

...bination With Peginterferon Alfa-2b in Treatment-Naive Patients With Chronic HCV; E.S. Maller, Monday, May 21, 2:15 p.m., Room 206 Phase II Study of celgosivir in combination with Peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype 1 nonresponder patients; K.D. Kaita, Monday, May 21, 2:45 p.m....
Celgosivir in Biological Technology

MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study

VANCOUVER and SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will add a 600mg celgosivir combination therapy arm to its currently enrolling Phase II viral kinetics study in hepatitis C virus ("HCV") ...

MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting

VANCOUVER and SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases will present results of viral resistance studies with its anti-HCV agent celgosivir at the 14th International Symposium on Hepatitis C Vir...

MIGENIX Reports First Quarter Fiscal 2009 Financial Results

...cal study program (previously Cutanea was targeting the end of 2008). celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; treatment of chronic hepatiti...e are continuing to seek strategic options for advancing the development of celgosivir and are currently in key partnering discussions. MX-2401 (IV lipopeptide;...

MIGENIX Corporate Update and Requisition of Special Meeting

...ayments and a single-digit royalty on net sales. celgosivir (oral alpha-glucosidase inhibitor for Hepatitis C ...rus infections): A Phase II study assessing 400 mg celgosivir for tolerability, pharmacokinetics and viral kinet...pment by the end of 2008; to have results from the celgosivir Phase II viral kinetics study in the next several ...

Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones

...nt payment(s), milestones and royalty terms celgosivir (hepatitis C virus): ----------------------------... - Program-related: The planned extension of the celgosivir viral kinetics study to include a 600 mg celgosivir combination arm (600 mg ...

MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results

...such a partnership(s) is uncertain at this time. celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; trea...y is currently enrolling patients to assess 600 mg celgosivir for tolerability, pharmacokinetics and viral kinet... to the standard of care drugs alone and to 400 mg celgosivir plus the standard of care for up to 12 weeks of th...

MIGENIX releases CEO message #22

...n H2/08 - NDA submission in H1/09 - Rest of world partnership celgosivir (hepatitis C virus): - Phase II viral kinetics study results (includi... application (NDA) being submitted for OmigardTM in the first half of 2009; celgosivir Phase II viral kinetic results in the third quarter 2008; CLS001 entering i...

MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results

...) for omiganan 1% gel in the first half of 2009. celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; trea...ncept and evidence of clinical benefit when adding celgosivir to the current standard-of-care HCV therapy (pegyl... (SVR). The safety profile for patients exposed to celgosivir for up to 48 weeks did not differ from those in th...

MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification

... Company to Report Interim celgosivir 4-Week Viral Kinetics Study Data on Monday December ...ort interim 4-week data from a Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection on Monday December 3, 2...

MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

... Company Provides Revised Timing on Interim celgosivir Viral Kinetics Study ... prevention of catheter-related infections - celgosivir - a Phase II product candidate for treating chroni...rom a Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infectio...
Other Tags
(Date:6/29/2015)... , ... June 29, 2015 , ... ... Medical Devices , **FDAnews Webinar**, July 16, 2015 — 1:30 p.m. – 3:00 ... ensure the application of human factors engineering to the design of new products ...
(Date:6/29/2015)... New York, New York (PRWEB) , ... June ... ... transvaginal mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against C.R. Bard, Inc. and ... According to court documents, the proceedings’ next Case Management Conference is to be ...
(Date:6/29/2015)... , ... June 29, 2015 , ... San Fernando ... lift and tighten sagging skin. Ulthera is a special treatment that offers a way ... ultrasound technology to gently stimulate collagen production. Ulthera is highly targeted and precise to ...
(Date:6/29/2015)... ... June 29, 2015 , ... Bionops Laboratories has ... Bio to French consumers. , The specialized eye health formulation contains a variety ... free radicals. In addition to Citicoline (Cognizin®), Biomacula provides necessary doses of Vitamin ...
(Date:6/29/2015)... ... June 29, 2015 , ... Blue Cross ... leaders with the Commercial Markets division, which includes the company’s commercial health plan ... companies with regional, national and international reach. Mary Ellen Anderson now holds the ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 2Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 3Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 3Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 2Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 3
(Date:6/17/2015)... Deutschland und GERMANTOWN, Maryland , June ... ®   Produktlinie mit DNA-Tests verbessert den ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) hat ... STR-Testkits der Produktlinie Investigator ® ... Markt eingeführt. Die neuen Kits zur Erstellung genetischer Fingerabdrücke ...
(Date:6/16/2015)... 16, 2015  With the increasing number and severity ... top concern. The recent compromise of Federal employee ... strong authentication within government agencies. HYPR Corp. ... password (OTP) authenticator, has been submitted for testing and ... 3 validation for tamper proofing. The ...
(Date:6/15/2015)... Conn. , Jun. 15, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces that ... be showcased to media at Digital Experience! @ NYC June ... summer showcase of the latest innovation in technology to over ... will be held at the Metropolitan Pavilion in ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
Other Contents